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HEALTH CARE REFORM
ORIGINAL INVESTIGATION
Forced Smoking Abstinence
Not Enough for Smoking Cessation
Jennifer G. Clarke, MD, MPH; L. A. R. Stein, PhD; Rosemarie A. Martin, PhD; Stephen A. Martin, MD;
Donna Parker, ScD; Cheryl E. Lopes, PhD; Arthur R. McGovern, PhD; Rachel Simon, BS;
Mary Roberts, MS; Peter Friedman, MD, MPH; Beth Bock, PhD
Importance: Millions of Americans are forced to quit
smoking as they enter tobacco-free prisons and jails, but
most return to smoking within days of release. Interven-
tions are needed to sustain tobacco abstinence after re-
lease from incarceration.
Objective: To evaluate the extent to which the WISE
intervention (Working Inside for Smoking Elimina-
tion), based onmotivational interviewing (MI) and cog-
nitive behavioral therapy (CBT), decreases relapse to
smoking after release from a smoke-free prison.
Design: Participants were recruited approximately 8
weeks prior to their release from a smoke-free prison and
randomized to 6 weekly sessions of either education vid-
eos (control) or the WISE intervention.
Setting: A tobacco-free prison in the United States.
Participants: A total of 262 inmates (35% female).
Main Outcome Measure: Continued smoking absti-
nence was defined as 7-day point-prevalence abstinence
validated by urine cotinine measurement.
Results: At the 3-week follow-up, 25% of participants
in theWISE intervention (31 of 122) and 7% of the con-
trol participants (9 of 125) continued to be tobacco ab-
stinent (odds ratio [OR], 4.4; 95% CI, 2.0-9.7). In addi-
tion to the intervention, Hispanic ethnicity, a plan to
remain abstinent, and being incarcerated for more than
6 months were all associated with increased likelihood
of remaining abstinent. In the logistic regression analy-
sis, participants randomized to the WISE intervention
were 6.6 times more likely to remain tobacco abstinent
at the 3-week follow up than those randomized to the
control condition (95%CI, 2.5-17.0). Nonsmokers at the
3-week follow-up had an additional follow-up 3months
after release, and overall 12% of the participants in the
WISE intervention (14 of 122) and 2% of the control par-
ticipants (3 of 125)were tobacco free at 3months, as con-
firmed by urine cotininemeasurement (OR, 5.3; 95%CI,
1.4-23.8).
Conclusions and Relevance: Forced tobacco absti-
nence alone during incarceration has little impact on
postrelease smoking status. A behavioral intervention pro-
vided prior to release greatly improves cotinine-
confirmed smoking cessation in the community.
Trial Registration: clinicaltrials.gov Identifier:
NCT01122589
JAMA Intern Med. 2013;173(9):789-794.
Published online April 8, 2013.
doi:10.1001/jamainternmed.2013.197
T OBACCO USE CONTRIBUTESto over 400 000 deathsannually.1 It is a majorcontributor to cancer andheart disease risk and is
the leading cause of preventable mor-
bidity, mortality, and health expense in
the United States resulting in an esti-
mated $157 billion in related annual
health and economic costs.2 Quitting
smoking reduces the risk of developing
smoking-related illnesses and the mor-
bidity and mortality associated with
these illnesses. In 2010, approximately
45.3 million American adults smoked,
an overall prevalence of 19.3%.3
One in 8 American smokers pass
through prisons and jails annually,4 and
since the announcement of the negative
health consequences of secondhand
smoke, correctional facilities are increas-
ingly becoming tobacco free: approxi-
mately 60% have complete smoking bans
(no tobacco products allowed anywhere
in the facility by inmates or staff).5 De-
spite this, 97% of inmates return to smok-
ing as soon as they are released back into
the community.4,6 Smoking among pris-
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oners is approximately 3 times that of the general popu-
lation,7 and minorities, poor, undereducated, and men-
tally ill individuals are all overrepresented in correctional
facilities.8 Despite the scale of this problem, few studies
have addressed the needs of incarcerated smokers.
Many successful interventions have been developed
for smoking cessation, but the success of smoking relapse–
prevention interventions is limited. Moreover, the avail-
able smoking-cessation and relapse-prevention treat-
ments do not address the unique and specific needs of
incarceratedmen andwomenwho have been tobacco free
formonths to years (forced-abstinent smokers), who have
completed the physical withdrawal from nicotine, and
who are returning to environmentswhere tobacco is avail-
able.9 Effective smoking relapse–prevention interven-
tions for this population will enhance our ability to at-
tain the Healthy People 2020 goal of decreasing smoking
rates to 12% among adults.10
Project WISE (Working Inside for Smoking
Elimination)11 is a randomized clinical trial of a smok-
ing abstinence intervention based onmotivational inter-
viewing (MI) and cognitive behavioral therapy (CBT),
which was developed to target the specific needs of in-
mates in a smoke-free prison about to be released to the
community.
METHODS
Complete details of the methods for this study have been de-
scribed elsewhere.11 Approvals from the institutional review
board and the office for human research protections were ob-
tained prior to any study activities. To further protect study par-
ticipants, a certificate of confidentiality was obtained.
PARTICIPANTS
Participants were recruited by research assistants (RAs) from
a large state correctional facility in the northeasternUnited States
(Figure 1) in which no tobacco products are allowed on site
by inmates or staff, and no pharmacotherapy or behavioral
therapy is routinely offered for smoking cessation. Sentenced
men and women were eligible for screening if they were to be
released within the next 8 weeks. In a confidential setting, RAs
explained the study and that participation was completely vol-
untary. Potential participants were eligible if they were 18 years
or older, smoked 10 or more cigarettes per day prior to incar-
ceration, and spoke English. Once a potential participant was
determined to be eligible andwilling to participate in the study,
the informed consent process was completed. All participants
received anAmericanHeart Association smoking-cessation pam-
phlet, a list of community resources, and study contact infor-
mation.
SAMPLE SIZE AND ATTRITION
Of the 312 people screened for the study, 2 did not speak Eng-
lish, 30 did not smoke10 cigarettes/d prior to incarceration,
7 had more than 8 weeks until release, 2 were homeless and
could not provide any contact information for follow-up, and
1 was not going to live in the follow-up area). Of the 273 eli-
gible persons, 262 (96.0%) agreed to participate and com-
pleted the consent procedure. Of the 262 enrolled and ran-
domized at baseline, 15 were excluded (from this report), 9
because of a computer error that did not save data from the base-
line questionnaire and 6 because they were still incarcerated
at the end of the study andhence could not be assessed for smok-
ing after release. Of the remaining 247 participants, 228 (92.3%)
completed the 3-week postrelease follow-up assessment. Non-
smokers at the 3-week follow-up were invited to return for a
3-month follow-up and 70% completed this assessment (28 of
40). Participants lost to follow-up were analyzed as smokers.
PROCEDURES
Following baseline assessment, participants were randomly as-
signed to either receive the WISE intervention or watch con-
trol videos. Randomizationwas stratified by sex, number of ciga-
rettes smoked in the 30 days prior to incarceration (20
cigarettes/d vs20 cigarettes/d), and postrelease smoking plans,
as previously described.11 Each study condition comprised 6
sessions that took place over approximately 6 weeks prior to
release. A 3-week postrelease follow-up, assessment included
taking a urine sample for cotinine evaluation, a computerized
assessment, and a timeline followback (TLFB) procedure12,13
to determine smoking behaviors on each day following release
from prison. Participants who were confirmed tobacco absti-
nent at 3-week follow-up were asked to return for a 3-month
postrelease assessment.
INTERVENTIONS
WISE Intervention
Sessions 1 and 6 of theWISE intervention involved MI, and in
sessions 2 through 5, participants received CBT.
Three RAs (with bachelor’s or equivalent degrees) received
approximately 24 hours of training, including didactic instruc-
tion, role playing, andworkingwith pilot participants. The RAs
were matched with sex-concordant participants. Two PhD-
level supervisors rated sessions to criteria using the Motiva-
tional Interviewing Treatment Integrity system, version 3.1.1,14
Assessed for eligibility312
Nonsmokers31
3-Week follow-up
(188/122) 96.7%
3-Month nonsmoker
follow-up rate
(23/31) 74.2%
Nonsmokers9
3-Week follow-up
(110/125) 88.0%
3-Month nonsmoker
follow-up rate
(5/9) 55.6%
Excluded50
Did not meet
inclusion criteria
39
Declined to participate11
WISE MI/CBT intervention130
Excluded8
No baseline data5
Never released3
Final122
Control132
Excluded7
No baseline data4
Never released3
Final125
Randomized262
Figure 1. Participant flowchart. CBT indicates cognitive behavioral therapy;
MI, motivational interviewing; WISE, Working Inside for Smoking
Elimination.11
JAMA INTERN MED/VOL 173 (NO. 9), MAY 13, 2013 WWW.JAMAINTERNALMED.COM
790
©2013 American Medical Association. All rights reserved.
Downloaded From: http://archinte.jamanetwork.com/ by a University of Rhode Island User  on 05/14/2013
and a key elements checklist for CBT sessions prior to RA con-
tact with participants. Supervision was conducted twice per
month and when treatment fidelity fell below criteria. Addi-
tional coaching was provided until sessions met standard. Ses-
sions were 30 to 60minutes long, and all were recorded. A ran-
dom 10% of sessions were coded for fidelity by supervisors, and
10% of those were double coded. There was over 90% agree-
ment in the coding in terms of proficient vs nonproficient, and
85% were proficient.
The research counselors’ therapeutic style and protocol were
based on the principles of MI, with a focus on empathy, not
arguing, developing discrepancy, self-efficacy, and personal
choice.15 TheCBT sessions taught participants to recognize spe-
cific environmental and affective events (triggers) that occur
prior to smoking and to identify behavioral and cognitive strat-
egies to copewith these triggers. Additional brief telephone ses-
sions were conducted at approximately 24 hours and 7 days
after the individual’s release. These sessions included ele-
ments of both MI and CBT in an effort to maintain and en-
hance motivation and use of skills after release.
Control Condition
The control videos included a variety of health-related topics
(eg, managing chronic pain) but did not target smoking ces-
sation and were matched with the WISE intervention for fre-
quency and duration of contact. Tomaintain frequency and du-
ration of contact, telephone calls were scheduled for
approximately 24 hours and 7 days after release; these calls veri-
fied contact information and assessed smoking status.
MEASURES
Full assessments, each taking about 60 minutes, occurred at
baseline and at 3 weeks following release. The RAs phoned par-
ticipants at 24 hours and 7 days after release for brief discus-
sion, and prior to discussion, smoking status was assessed. As-
sessments at baseline and 3-week follow-up were conducted
using audio computer-assisted self-interviews. Assessments in-
cluded demographics, smoking history and dependence (Fag-
erstro¨m Test for Nicotine Dependence [FTND]modified to re-
flect time prior to incarceration),16 subjective stress (Perceived
Stress Scale),17 presence or absence of smoking-related ill-
nesses (asthma, diabetes, hypertension, stroke, or heart attack),
and depressive symptoms (Center for Epidemiologic Studies
Depression Scale [CES-D]).18 Participation in a prison drug treat-
ment program was assessed with the question “have you par-
ticipated in a drug treatment program?”Many prison drug treat-
ment programs use CBT and MI (similar to the WISE
intervention).
Intention to remain tobacco free was measured using a
6-point scale and dichotomized: responses of “I plan to smoke
when I get out of here and never plan to quit” to “I will prob-
ably smoke when I get out of here” were classified as “plans to
smoke upon release.” Responses of “I probably won’t smoke
when I get out of here” to “I have made plans to not smoke
when I get out. and I will never smoke again” were classified
as “plans to not smoke upon release.” At the 3-week follow-
up, a urine sample was obtained to test for cotinine and other
substance use, and a detailed TLFB12,13 was administered to as-
sess tobacco use. An additional urine cotininemeasurementwas
obtained 3 months after release from participants who tested
negative for cotinine at the 3-week follow-up.Continued smok-
ing abstinencewas defined as testing negative for cotinine (uri-
nary cotinine level, 200 ng/mL) and reporting no smoking
in the previous 7 days; all others were considered smokers.19
ANALYSES
Weexamined baseline differences between conditions on demo-
graphic and smoking variables using 2 tests of proportions for
categorical variables and t tests for continuous variables. To be
considered having completed the study, a participant had to
complete a 3-week follow-up interview and provide a urine
sample. We examined other variables that might predict out-
come in this sample by comparing those with sustained absti-
nence to those who smoked. These included sex, age, years of
education, race/ethnicity, measures of affective symptoms and
vulnerability (CES-D, Perceived Stress Scale), prison drug treat-
ment, and smoking-related variables includingFTNDscore, ciga-
rettes smoked per day prior to incarceration, time since smoked
daily, age started smoking daily, number of years of daily smok-
ing, smoking plans after release, presence of smoking-related
medical condition, and presence of a spouse/partner who
smokes.
Analyses of sustained abstinence at 3weeks after release used
the full intention-to-treat sample and used logistic regression.
In the first model, we entered treatment group only. The sec-
ondmodel adjusted for other variables related to sustained ab-
stinence with a level of significance set at P.10. Time since
smoked daily was dichotomized (6 months vs 6 months)
because it was highly skewed.
Wenext conducted discrete-time survival analysis usingCox
proportional hazards regression models to test the hypothesis
that the risk of returning to smoking was significantly higher
for participants randomized to the control condition com-
pared with participants in the WISE intervention. All analyses
were conducted using SPSS statistical software, version 20 (IBM
Corp).
RESULTS
PARTICIPANT CHARACTERISTICS
The sample (N=247) comprised the following racial/
ethnic background: 20.1%Hispanic, 17.6% black, 52.0%
white, and 10.2% self-identified as other and did not dif-
fer by intervention group (Table 1). Most participants
weremen (65.2%);mean agewas 35.6 years; and themean
time since the last cigarette was 1.5 years. Intervention
groups did not differ significantly at baseline on depres-
sion, stress, demographic, or smoking variables (Table 1).
All 6 WISE intervention sessions were completed by
83.3%, with 11.9% completing 3 or fewer sessions.
Analysis comparing WISE and control participants
on confirmed smoking status 3 weeks after release found
participants randomized to the WISE intervention were
4.4 (95% CI, 2.0-9.7) times more likely to remain to-
bacco abstinent than those randomized to the control con-
dition (Table 2). Significant differences (P  .10) were
found between smokers and nonsmokers: Those not
smoking at the 3-week follow-up started smoking when
theywere older (age 17.3 vs 15.4 years) (P = .02), smoked
for fewer years (16.6 vs 19.9 years) (P = .06), were more
likely to have participated in prisondrug treatment (63.2%
vs 47.3%) (P = .07), had gone longer since smoking regu-
larly (2.5 vs 1.4 years) (P = .06), were more likely to be
Hispanic (33.3% vs 17.6%) (P = .02), and planned not
to smoke after release from prison (62.5% vs 46.1%)
(P = .06).We therefore controlled for these variables in our
multivariate logistic regression.
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In the multivariate logistic regression (Table 3), ran-
domization to the intervention group remained a signifi-
cant predictor of abstinence at 3 weeks (odds ratio [OR],
6.6; 95% CI, 2.5-17.0) compared with those random-
ized to the control condition. Hispanic ethnicity was also
associatedwith greater tobacco abstinence at 3weeks (OR,
3.2; 95% CI, 1.1-8.7), as was not smoking for 6 or more
months (OR, 4.6; 95%CI, 1.7-12.4) and planning to not
smoke (OR, 1.6; 95% CI, 1.2-2.3).
Participants who were abstinent at their 3-week fol-
low-up (n = 40)were reevaluated at 3months. In the con-
trol group, 2.4% (3 of 125) were cotinine-confirmed ab-
stinent compared with 11.5% (14 of 122) in the
intervention group (OR, 5.3; 95% CI, 1.4-23.8). How-
ever, follow-up data were obtained on only 28 (70%) of
the 40 nonsmokers.
An adjusted survival curve usingCoxproportional haz-
ards model is depicted in Figure 2 and includes days
to first cigarette from the TLFB data. The first day in the
community was the highest-risk day, whenmost partici-
pants relapsed to smoking. After day 1, the rate of re-
lapse declined sharply, with the intervention groupmain-
taining significantly better survival (P = .001). In the
survivalmodel examining days to first smoking lapse, the
main effect of treatment conditionwas significant, (SE),
0.56 (0.16); hazard ratio, 1.75 (P = .001), indicating that
the risk of smoking after release was over 1.75 times
greater for those in the control condition than for those
in the WISE intervention.
COMMENT
To our knowledge, this is the first study to demonstrate
an effective intervention to prevent smoking relapse af-
ter release from a prison with a complete tobacco ban.
The abstinence rates were 25.4% and 7.2% at 3 weeks
and 11.5% and 2.4% at 3 months in the WISE interven-
tion and control groups, respectively. The situation of
forced tobacco abstinence during incarceration is unique
in that incarcerated people have no choice about abstain-
ing from tobacco; they have completed nicotine with-
drawal; and they face reexposure to tobacco once re-
leased. Therefore, comparisons with other interventions
Table 1. Participant Randomization
and Baseline Characteristicsa
Characteristic
Total
(n = 247)
WISEb
(n = 122)
Control
Video
(n = 125)
Race/ethnicity
White 127 (52.0) 63 (51.6) 64 (52.5)
Hispanic 49 (20.1) 26 (21.3) 23 (18.9)
Black, non-Hispanic 43 (17.6) 21 (17.2) 22 (18.0)
Other 25 (10.2) 12 (9.8) 13 (10.7)
Sex
Male 161 (65.2) 80 (65.6) 81 (64.8)
Female 86 (34.8) 42 (34.4) 44 (35.2)
Smoking plans
Plan to smoke after release 126 (51.2) 65 (53.3) 61 (49.2)
Plan to not smoke after release 120 (48.8) 57 (46.7) 63 (50.8)
Education level completed
High school 157 (64.6) 81 (66.4) 76 (62.8)
High school 49 (20.2) 21 (17.2) 28 (23.1)
High school 37 (15.2) 20 (16.4) 17 (14.0)
Reported health status
Poor-fair 75 (30.7) 41 (33.6) 34 (27.9)
Good-excellent 169 (69.3) 81 (66.4) 88 (72.1)
In-prison drug treatment 119 (49.8) 56 (47.1) 63 (52.5)
Smoking-related medical
conditions
89 (36.0) 44 (36.1) 45 (36.0)
Age, yc 35.6 (9.2) 35.4 (9.4) 35.7 (9.0)
Age started smoking daily, yc 15.7 (4.5) 15.6 (4.7) 15.9 (4.3)
Years of smokingc 19.4 (10.0) 19.1 (10.0) 19.7 (10.0)
Time since smoked daily, yc 1.5 (3.4) 1.6 (3.4) 1.5 (3.5)
Cigarettes/d prior to prison,
No.c
21.7 (11.7) 20.7 (10.6) 22.6 (12.8)
FTNDc 5.1 (2.3) 5.2 (2.2) 5.1 (2.4)
PSSc 21.8 (6.3) 21.5 (7.0) 22.2 (5.6)
CES-Dc 12.7 (5.4) 12.4 (5.6) 13.0 (5.3)
Abbreviations: CES-D, Center for Epidemiologic Studies Depression
Scale18; FTND, Fagerstro¨m Test for Nicotine Dependence,16 modified to reflect
time prior to incarceration; PSS, Perceived Stress Scale17; WISE, Working
Inside for Smoking Elimination.11
aUnless otherwise indicated, data are reported as number (percentage) of
participants.
bP .20 for all treatment group differences.
cData reported as mean (SD) values.
Table 2. Nonsmokers vs Smokers at 3-Week Follow-upa
Characteristic
Nonsmoker
(n = 40)
Smoker
(n = 207)
Intervention condition
WISE intervention 31 (25.4) 91 (74.6)c
Control video 9 (7.2) 116 (92.8)c
Female 14 (35.0) 72 (34.8)
Education level completed
High school 24 (61.5) 133 (65.2)
High school 9 (23.1) 40 (19.6)
High school 6 (15.4) 31 (15.2)
Race/ethnicity
White 17 (43.6) 110 (53.7)
Hispanic 13 (33.3) 36 (17.6)d
Black, non-Hispanic 5 (12.8) 38 (18.5)
Other 4 (10.3) 21 (10.2)
Smoking plans
Plan to smoke upon release 15 (37.5) 111 (53.9)e
Plan to not smoke upon release 25 (62.5) 95 (46.1)
Smoking-related medical conditions 17 (42.5) 72 (34.8)
Spouse/partner smokes 18 (51.4) 102 (60.4)
Drug use prior to incarceration 35 (87.5) 194 (93.7)
In prison drug treatment 24 (63.2) 95 (47.3)e
Age, yb 35.2 (9.4) 35.7 (9.2)
Age started smoking daily, yb 17.3 (5.6) 15.4 (4.2)d
Years of smokingb 16.6 (9.1) 19.9 (10.1)e
Time since smoked daily, yb 2.5 (2.4) 1.4 (3.6)e
Cigarettes/d prior to prison, No.b 19.0 (9.5) 22.1 (12.1)
FTNDb 4.9 (2.3) 5.2 (2.3)
PSSb 21.5 (6.1) 21.9 (6.3)
CES-Db 12.3 (4.9) 12.8 (5.5)
Abbreviations: CES-D, Center for Epidemiologic Studies Depression
Scale18; FTND, Fagerstro¨m Test for Nicotine Dependence,16 modified to reflect
time prior to incarceration; PSS, Perceived Stress Scale17; WISE, Working
Inside for Smoking Elimination.11
aUnless otherwise indicated, data are reported as number (percentage)
of participants.
bData reported as mean (SD) values.
cP  .01 for differences between smokers and nonsmokers.
dP  .05 for differences between smokers and nonsmokers.
eP  .10 for differences between smokers and nonsmokers.
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are limited in their application and scope.Many smoking-
cessation interventions focus on setting a quit date and
remaining abstinent; however, in this setting the quit date
is forced by someone other than the tobacco user. For
those who had smoked prior to incarceration, there is
no choice in quit date, and it is only on the date of re-
lease when there is a choice to be made about remaining
abstinent or returning to smoking.
Results of theWISE intervention are better than those
found in many other studies on behavioral intervention
for smokers. On average,MI leads to an increase in smok-
ing cessation with a risk reduction (RR) of 1.27.20 Indi-
vidual counseling is more effective than the control con-
dition with an RR for smoking cessation of 1.39 (95%
CI, 1.24-1.57).21 Our results may be greater because of
the enforced abstinence prior to the intervention. In ad-
dition, participants who had not smoked for 6 months
or longer at the time of the intervention were 4.6 times
as likely to be abstinent at 3 weeks compared with those
who smokedwithin the past 6months. This suggests that
prolonged forced abstinence can improve smoking out-
comes. However, without intervention, only 2.4% of par-
ticipants remained tobacco free at 3 months after re-
lease. Results may also be related to the relatively brief
follow-up period; future research should examine this is-
sue. Similar to other studies, our study found the early
postrelease period to be an extremely high-risk time,22,23
with more than 60% of control participants relapsing to
smoking the first day out.
We chose not to include pharmacotherapy in this in-
tervention because we could find no evidence support-
ing the use of medications after prolonged tobacco ab-
stinence. Contraband tobacco products exist in prisons,
but the majority of inmates will not use them because of
the high costs ($10 per cigarette, according to several in-
mates) and consequences.24 The higher the level of se-
curity, the more difficult it is to access cigarettes. Medi-
cations have enhanced smoking cessation: varenicline
showed an RR of 2.27 (95% CI, 2.02-2.55)25; bupropion
RR, 1.69 (95% CI, 1.53-1.85)26; and nicotine replace-
ment therapy RR, 1.58 (95%CI, 1.50-1.66).27While these
studies all had longer follow-up periods, the effect of our
behavioral intervention is comparable.
One of the national health objectives for 2020 is to
reduce the prevalence of cigarette smoking to less than
12%.28 Effective smoking-cessation programs targeting
incarcerated people are necessary to reach this goal be-
cause approximately 9 million individuals (5.4 mil-
lion smokers) return to the community from correc-
tional facilities annually.4 Tobacco use among prisoners
is approximately 3 times that of the general popula-
tion.7 Smoking-cessation interventions targeting this high-
risk and underserved population are instrumental to de-
crease health disparities and decrease tobacco-related
illnesses in this vulnerable population.
Further investigation is needed. Our study’s strengths
include a diverse population (52%non-Hispanic whites),
inclusion of all smokers regardless of motivation to re-
main abstinent after release, cotinine verification of smok-
ing status, and a follow-up rate over 90%. The study’s
limitations include follow-up after release from prison
limited to 3 weeks for all participants; however, partici-
pants not smoking at the 3-week follow-up visit were in-
vited to follow up at 3 months after release to assess for
continuous abstinence. Because this is the first study of
this population, and relapse rates are precipitously high
immediately after release, we believed that a brief fol-
low-up period for all participants was appropriate, with
longer follow-up of the nonsmokers. Further investiga-
tion with longer postrelease follow-up is needed. Also,
the study was limited to a sentenced population. Many
of the 9 million people released from prisons and jails
every year have been imprisoned there for less than 3
months and do not have specific release dates. Evalua-
tions of smoking cessation interventions are needed for
inmates at the time of entry to prisons and jails.
In summary, our study shows that an intervention
based on MI and CBT can improve continued smoking
abstinence after prison release by 6.6 times over that of
the control condition. Behavioral intervention for drug
use is common in prison settings,29 and so this interven-
tion may be easily integrated into and transported to ex-
isting programs in prison settings. Future studies may
wish to dismantle the treatment to streamline into the
most effective components. Additionalwork is also needed
to examine methods for providing postrelease interven-
tion to help sustain longer-term abstinence.
Table 3. Logistic Regression
Variable  (SE)
P
Value OR (95% CI)
WISE intervention 1.9 (0.5) .01 6.6 (2.5-17.0)
In prison 6 mo 1.5 (0.5) .01 4.6 (1.7-12.4)
Hispanic 1.2 (0.5) .03 3.2 (1.1-8.7)
Smoking plans 0.5 (0.2) .01 1.6 (1.2-2.3)
Cigarettes/d prior to prison,
No.
0.03 (0.02) .10 1.0 (0.9-1.0)
In-prison drug treatment 0.6 (0.5) .16 1.9 (0.8-4.6)
Abbreviations: OR, odds ratio; WISE, Working Inside for Smoking
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Figure 2. Tobacco abstinence at the 3-week follow-up by the study condition
group (adjusted survival curves). *Effect seen in treatment group is
significant (P=.001) ( [SE], 0.56 [0.16]; hazard ratio, 1.75), indicating that
the risk of smoking after release was over 1.75 times greater for those in the
control condition compared with those in the WISE (Working Inside for
Smoking Elimination11) intervention.
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